Monarch
Payments companies reported to CMS as associated with Monarch. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Monarch, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Monarch
These are the largest totals companies reported as associated with Monarch. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Machuzak | Cleveland, OH | Pulmonary Disease | $48,341.80 |
| Faisal Khan | Greenwood, IN | Pulmonary Disease | $26,486.28 |
| Omar Ibrahim | Farmington, CT | Pulmonary Disease | $19,143.11 |
| Gustavo Cumbo Nacheli | Grand Rapids, MI | Pulmonary Disease | $18,444.31 |
| Raed Alnajjar | Detroit, MI | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $13,926.65 |
| Ismael Matus | Newark, DE | Pulmonary Disease | $13,524.47 |
| Thomas Chi | Birmingham, AL | Urology | $13,329.58 |
| Nicholas Baker | Pittsburgh, PA | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $12,001.53 |
| Christopher Manley | Philadelphia, PA | Pulmonary Disease | $9,663.01 |
| Grant Pierson | Joplin, MO | Pulmonary Disease | $9,618.99 |
Prescribed Monarch?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.